Bevacizumab with SECOND LINE fluoropyrimidine-based chemotherapy [BEV12]

For metastatic or locally advanced and inoperable colorectal cancer where the following criteria have been met:

1. This application for bevacizumab is being made by, and the first cycle of systemic anti-cancer therapy will be prescribed by a consultant specialist specifically trained and accredited in the use of systemic anti-cancer therapy.
2. The patient has either metastatic or locally advanced and inoperable colorectal carcinoma and has received ONE prior line of systemic therapy for this indication.

Note

Note: patients may also/additionally have received neoadjuvant systemic therapy for non-metastatic disease and/or adjuvant chemotherapy after surgery.

3. The patient’s tumour has a documented presence of microsatellite stability (MSI-S) or DNA mismatch repair proficiency (pMMR) confirmed by validated testing, OR the patient received immunotherapy as their first line treatment, OR immunotherapy is not being used as second line therapy due to its unsuitability for this patient

• patient has MSI-S/pMMR tumour
• patient received immunotherapy as their first line treatment
• immunotherapy (e.g. ipilimumab/nivolumab/pembrolizumab) is not suitable for this patient

4. The patient’s tumour is either BRAF V600E mutation NEGATIVE, or the patient received cetuximab/panitumumab as part of first line therapy, or the patient is not suitable for 2nd line treatment with encorafenib in combination with cetuximab as per form ENC2

• patient has a tumour which is BRAF V600E mutation negative
• patient received cetuximab/panitumumab as part of 1st line therapy
• the combination of encorafenib and cetuximab is not suitable for this patient

5. The patient will receive 2nd line fluoropyrimidine based chemotherapy alongside bevacizumab as shown below

• the patient will receive irinotecan plus infusional 5FU (FOLFIRI)
• the patient will receive oxaliplatin plus infusional 5FU (FOLFOX)
• the patient will receive oxaliplatin plus capecitabine (CAPOX)
• the patient will receive single agent capecitabine or single agent infusional 5FU
• the patient will receive an alternative fluoropyrimidine based chemotherapy regimen

6. Bevacizumab will be stopped on disease progression or unacceptable toxicity or withdrawal of patient consent whichever occurs first. Note – Patients who move to 3rd line treatment may continue to receive bevacizumab with trifluridine plus tipiracil if this is the most appropriate third line regimen, and the patient meets all of the criteria on form TRI3
7. When a treatment break of more than 6 weeks beyond the expected 2, or 3 - weekly cycle length is needed, a treatment break approval form will be completed to restart treatment. This MUST be approved before treatment is re- started.
8. Bevacizumab will be otherwise used as set out in its Summary of Product Characteristics (SPC).

NHS funded From: 24 December 2025

Additional information

Form version: -

CDF Managed Access: NA

NICE Technology Appraisal: n/a (NA)

Current Form Version

Note

The data on this page was produced using version 1.385 of the CDF list, downloaded from NHS England’s website on 27 January 2026 at 22:25.

If NHS England has published a new version of the CDF List but this site has not yet accessed that, this form may be out of date. Additionally, if any update has occurred without NHS England noting it as a change, this page will be out of date.

Older Form Versions

There are previous versions of this form. These may not all be available on this site.